The Food and Drug Administration (FDA) has approved Welireg ™ (belzutifan) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara.

With an increasing geographic footprint, it is important for clinicians to be able to recognize and treat coccidioidomycosis, or valley fever, in susceptible patient populations.